Review of P-Glycoprotein on the Blood-Cerebrospinal Fluid Barrier

doi:10.3969/j.issn.2095-1396.2016.02.009

Abstract

Abstract: Blood-cerebrospinal fluid barrier（blood-CSF barrier） is a dynamic physiological structure，which is composed of brain microvascular endothelial cells，astrocytes and pericytes，playing an important role in maintaining homeostasis in the central nervous system（CNS）. P-glycoprotein（P-gp） is a common membrane protein in the blood cerebrospinal fluid barrier，which is expressed in the brain microvascular endothelial cells，and it limits the toxic substances and a large number of drugs for the treatment of the central nervous system into the brain. Therefore the efflux transport mechanism of P-gp in the blood-CSF barrier is a break though point for the treatment of nervous system disease. This article mainly reviews research progress on the basic structure and trans-port mechanism of P-gp，it’s regulation mechanism in the physiological and pathological conditions and inhibitors，to provide references for drug development and blood-CSF barrier transport mechanism of CNS.

Key words: P-glycoprotein, basic structure, transport mechanism, regulation mechanism, inhibitor

CLC Number:

R964

ZHANG Hai-wei，ZHANG Li. Review of P-Glycoprotein on the Blood-Cerebrospinal Fluid Barrier[J]. Acta Neuropharmacologica, 2016, 6(2): 53-64.

References

[1] 马金柱, 王化磊, 郑学星, 等. 天然免疫屏障-血脑屏障调节的研究进展[J]. 细胞与分子免疫学杂志, 2013, 29(8): 885-888.

[2] 周曼, 杨万超, 刘翔, 等. 血脑屏障结构功能及体外模型的研究进展[J]. 疑难病杂志, 2014, 13(6): 647-649.

[3] 张珉, 张俊钰, 钟武. 血脑屏障开放方法研究进展[J]. 国际药学研究杂志, 2016, 43(1): 126-133.

[4] 王玉璘，王少峡，郭虹，胡利民.血脑屏障中P-糖蛋白的调节机制[J]. 中国药理学通报, 2011, 27(9): 1196-2000.

[5] David S Miller. Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrier[J]. Trend Pharmacol Sci, 2010, 31(6): 246-254.

[6] Remi-Martin Laberge, Raghuram Ambadipudi, Elias Georges. P-glycoprotein mediates thecollateral sensitivity of multidrug resistant cells to steroidhormones[J]. Biochem Biophys Res Commun, 2014, 447(4): 574-579．

[7] Juliano R L, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J]. Biochim Biophys Acta, 1976, 455(1): 152-162.

[8] Munekazu Nakaichi, Yoko Takeshita, Masaru Okuda, et al. Expression of the MDR1 gene and P-glycoprotein in canine mast cell tumor cell lines[J]. J Veterinary Medical Science, 2007, 69: 111-115.

[9] 牛芳，周芳，吴晓兰，等. 血脑屏障上ABC转运体与中枢神经系统疾病相关性的研究进展[J]. 中国临床药理学与治疗学, 2012, 17(2): 225-233.

[10] 涂春华，杨冬梓. P-糖蛋白结构及作用机制[J]. 中国生物化学与分子生物学, 2009, 25(1): 7-11.

[11] 吴松笛，万琪. 血脑屏障ATP结合盒超家族转运蛋白和药物转运[J]. 国外医学：脑血管疾病手术分册, 2005, 13(5): 386-389.

[12] Annie Frelet, Markus Klein. Insight in eukaryotic ABC transporter function by mutation analysis[J]. Febs Letters, 2006, 580(4): 1064-1084.

[13] Lin Jiunn H, Masayo Yamazaki. Role of P-glycoprotein in pharmacokinetics-clinical implications[J]. Clin Pharmacokinet, 2003, 42(1): 59-98.

[14] Michael Hohl, Christophe Briand, Markus G Grütter, et al. Crystal structure of a hete-rodimeric ABC transporter in its inward-facing conformation[J]. Nature Str-uctural&Molecular Biology, 2012, 19(4): 395-402.

[15] Chitra A Shintre, Ashley C W Pike, Li Qiu-hong, et al. Structures of ABCB10 a human ATP-binding cassette transporter in apo- and nucleotide-bound states[J]. Proc Natl Acad Sciences USA, 2013, 110(24): 9710-9715.

[16] Suresh V Ambudkar, Saibal Dey, Christine A Hrycyna. Biochemical, cellular, and pharmacolo-gical aspects of the multidrug transporter[J]. Annual Review of Pharmacology and Toxicology, 1999, 39, 361-398.

[17] 袁洪雨. 喹喔啉酮类P-糖蛋白抑制剂的设计、合成及逆转肿瘤多药耐药活性研究[D].济南：山东大学, 2009.

[18] Karin Pleban, Stephan Kopp, Edina Csaszar, et al. P-glycoprotein substratebinding domains are located at the transmembrane domain transmembrane domain interfaces:a combined photoaffinity labeling-protein homology modeling approach[J]. Mol Pharmacol, 2005, 67(2): 365-374.

[19] Miguel R Lugo, Frances Jane Sharom. Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs[J]. Biochemistry, 2005, 44(42): 14020-14029.

[20] Christopher F Higgins, Kenneth J Linton. The ATP switch model for ABC transporters[J]. Nat StructMol Biol, 2004, 11(10): 918-926.

[21] Suresh V Ambudkar, In-Wha Kim, Zuben E Sauna. The power of the pump:mechanisms of action of P-glycoprotein(ABCB1) [J]. Eur J Pharm Sci, 2006, 27: 392-400.

[22] Gabriel E Jara, D Mariano A Vera, Adriana B Pierini. Binding of modulators to mouse and human multidrug resistance P-glycoprotein. A computational study[J]. J Molecular Graphics Modelling, 2013, 46: 10-21.

[23] Freya Klepsch, Poongavanam Vasanthanathan, Gerhard F Ecker. Ligand and structure-based classi-fication models for prediction of P-glycoprotein inhibitors[J]. J Chem Inf Model, 2014, 54(1): 218-229.

[24] Wen Po-chan, Brandy Verhalen, Stephan Wilkens, et al. On the origin of large flexibility of P-glycoprotein in the inward-facing state[J]. J Biological Chemistry, 2013, 288: 19211-19220.

[25] Jessica H van Wonderen, Roisin M McMahon, Megan L O'Mara, et al. The central cavity of ABCB1 undergoes alternating access during ATP hydrolysis[J]. FEBS J, 2014, 281(9): 2190–2201.

[26] Ricardo J Ferreira, Maria-Jose U Ferreira, Daniel J V A dos Santos, et al. Insights on P-glycoprotein’s efflux mechanism obtained by molecular dynamics simulations[J]. J Chemical Theory and Computation, 2012, 8(6): 1853-1864.

[27] Justin Charles Jagodinsky, Ugur Akgun. Characterizing the binding interactions between P-glycoprotein and eight known cardiovascular transport substrates[J]. Pharmacology Research & Perspectives, 2015, 3: e00114.

[28] Nandhitha Subramanian, Karmen Condic-Jurkic, Alan Edward Mark, et al. Identification of possi-ble binding sites for morphine and nicardipine on the multidrug transporter P-glycoprotein using umbrella sampling techniques[J]. J Chemical Information Modeling, 2015, 55(6): 1202-1217.

[29] Nandhitha Subramanian, Alexandra Schumann-Gillett, Alan E Mark, et al. Understanding the accumulation of P-glycoprotein substrates within cells: The effect of cholesterol on membrane partitioning[J]. Biochimica et Biophysica Acta (BBA) Bi-omembranes, 2016, 1858(4): 776-782.

[30] Suresh V Ambudkar, In-Wha Kim, Zuben E Sauna, et al. The Aloop,a novel c-onserved aromatic acid subdomain upstream of the Walker A motif in AB-C transporters,is critical for ATP binding[J]. FEBS Lett, 2006, 580(4): 1049-1055.

[31] Yurika Watanabe, Wei-lin Hsu, Shuntaro Chiba, et al. Dynamics and structural changes induced by ATP and/or substrate binding in the inward-facing conformation state of P-glycoprotein[J]. Chemical Physics Letters, 2013, 557: 145-149.

[32] Megan L O’Mara, Alan E Mark. Structural characterization of two metastable ATP-bound states of P-glycoprotein[J]. PLoS ONE, 2014, 9(3): e91916.

[33] Zuben E Sauna, In-Wha Kim, Suresh V Ambudkar. Genomics and the mechanis-m of P-glycoprotein(ABCB1)[J]. J Bioenerg Biomembr, 2007, 39(5): 481-487.

[34] Catherine Vigano, Michel Julien, Isabelle Carrier, et al. Structural and functional asymmetry of the nucleotide-binding domains of P-glycoprotein investigated by attenua-ted total reflection Fourier transform infrared spectroscopy[J]. J Biological Chemistry, 2002, 277(7): 5008-5016.

[35] Suresh V Ambudkar, In-War Kim, Zuben E Sauna. The power of the pump: mechanisms of action of action of P-glycoprotein(ABCB1) [J]. Eur J Pharm Sci, 2006, 279(5): 392-400.

[36] Michael Hohl, Christopher Briand, Markus G Grütter, et al. Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation[J]. Nature Structural & Molecular Biology, 2012, 19(4): 395-402.

[37] Chitra A Shintre, Ashley C W Pike, Li Qiu-hong. Structures of ABCB10, a human ATP-bi-nding cassette transporter in apo- and nucleotide-bound states[J]. Proceedings of the National Academy of Sciences USA, 2013, 110: 9710-9715.

[38] Roger J P Dawson, Kaspar P Locher. Structure of a bacterial multidrug ABC transporter[J]. Nature, 2006, 443: 180-185.

[39] Hassanul G Choudhury, Zhen Tong, Indran Mathavan, et al. Structure of an antibacterial peptide ATP-binding cassette transporter in a novel outward occluded state[J]. Proceedings of the National Academy of Sciences USA, 2014, 111(25): 9145-9150.

[40] Aller S G, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding[J]. Science, 2009, 323: 1718-1722.

[41] 聂昊，王晖. P糖蛋白在不同组织中的分布与功能研究进展[J]. 广东药学学报, 2012, 28(4): 456-460.

[42] Luscher A, Harry P de Koning, Master P. Chemotherapeeutic strategies against Trypanosoma brucei: Drug targets vs. drug targeting[J]. Current Pharmaceutical Design, 2007, 13(6): 555-567.

[43] Nandhitha Subramanian, Karmen Condic-Jurkic, Megan L O Mara. Structural and dynamic perspectives on the promiscuous transport activity of P-glycoprotein[J]. Neurochemistry International, 2016, 10: 1016.

[44] 韩嘉华，朱斯琦，谢燕. 黄酮类化合物抵抗P-糖蛋白介导肿瘤多药耐药特性机制研究进展[J]. 国际药学研究杂志, 2016, 43(5): 818-823.

[45] Zhu Li-tao, Zhao Li, Wang Hu, et al. Oroxylin A reverses P-glycoprotein mediated multidrug resistance of MCF7/ADR cells by G2/M arrest[J]. Toxicol Lett, 2013, 219(2): 107-115.

[46] Zhao Bo-xin, Sun Ya-bin, Wang Sheng-qi, et al. Grape seed procyanidin reversal of P-glycoprotein associated multidrug resistance viadown-regulation of NF-κB and MAPK/ERK mediated YB-1 activity in A2780/T cells[J]. PLoS One, 2013, 8(8): e71071.

[47] Xia Yuan-zheng, Ni Kai, Guo Chao, et al. Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-κB sig-naling[J]. Phytomedicine, 2015, 22(3): 344-351.

[48] 赵博欣. 原花青素通过抑制P-糖蛋白功能与表达从而逆转肿瘤多药耐药作用的机制研究[D]. 深圳：南方科技大学, 2014.

[49] 董会月. 丹皮酚逆转人白血病耐药细胞系K562/ADM细胞多药耐药的作用研究[D]. 福建：福建中医药大学, 2010.

[50] 周勇，钟文彬，陈凯,等. Disulfiram联合Cu通过上调TNF-α表达及蓄积ROS诱导白血病干细胞凋亡[J]. 第三军医大学学报, 2015, 37(10): 984-989.

[51] 何海兰，季丽娟，李琦智, 等. 槲皮素对阿霉素诱导HL-60细胞MDR1基因表达的影响[J]. 中国实验血液学杂志, 2015, 23(1): 70-76.

[52] 刘小微，王慧君，梁伟, 等. 从Akt/COX-2/P-gp信号通路研究丹参酚酸B逆转HCT-8/VCR细胞多药耐药的作用及机制[J]. 中国中西医结合消化杂志, 2016, 2(5): 338-344.

[53] Anika M S Hartz, Bjorn Bauer, Gert Fricker, et al. Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1[J]. Molecular Pharmacology, 2004, 66(3): 387-394.

[54] Robert R Rigor, Brian T Hawkins, David S Miller. Activation of PKC isoform beta(I) atthe blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drugdelivery to the brain[J]. J Cerebral Blood Flow and Metabolism, 2010, 30(7): 1373-1383.

[55] Wang Xue-qian, Brian T Hawkins, David S Miller. Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier[J]. FASEB J, 2011, 25(2): 644-652.

[56] Brian T Hawkins, Robert R Rigor, David S Miller. Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated usin-g a novel in situ proteolysis protection assay[J]. J Cerebral Blood Flow and Metabolism, 2010, 30(9): 1593–1597.

[57] Brian T Hawkins, Destiny B Sykes, David S Miller. Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor[J]. J Neurosci, 2010, 30(4): 1417-1425.

[58] David S Miller. ABC transporter regulation by signaling at the blood-brain barrier: relevance to pharmacology[J]. Advances in Pharmacology, 2014, 71:1-24.

[59] Rashid Deane, Wu Zhen-hua, Berislav V Zlokovic. RAGE(yin) versus LRP(yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier[J]. Stroke, 2004, 35(11 suppl 1): 2628-2631.

[60] Fred C Lam, Liu Rong-hua, Lu Pei-hua, et al. β-Amyloid efflux mediated by p-glycoprotein[J]. J Neurochem, 2001, 76(4): 1121-1128.

[61] Anika M S Hartz, David S Miller, Bjorn Bauer. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer’s disease[J].Mol Pharmacol, 2010, 77(5): 715-723.

[62] Silke Vogelgesang, Ingolf Cascorbi, Eike Schroeder, et al. Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans[J]. Pharmacogenetics, 2002, 12(7): 283-296.

[63] Silke Vogelgesang, Rolf W Warzok, Ingolf Cascorbi, et al. The role of P-glycoprotein in cerebral amyloid angiopathy: Implications for the early pathogenesis of Alzheimer’s disease[J]. Curr Alzheimer Res, 2004, 1(2): 121-125.

[64] Anja Brenn, Markus Grube, Michele Peters, et al. Beta-amyloid downregulates MDR1 P-Glycoprotein(ABCB1) expression at the blood-brain barrier in mice[J]. Int J Alzheimers Dis, 2011, 2011: 690121.

[65] Diana Kuhnke, Gabriele Jedlitschky, Markus Grube, et al. MDR1-P-Glycoprotein(ABCB1) mediates transport of Alzheimer’s amyloid-beta peptides-implications for the mechanisms of Aβ clearance at the blood-brain barrier[J]. Brain Pathol, 2007, 17(4): 347-353.

[66] 张觅，张啟智，楼江, 等. P-糖蛋白在退行性疾病中的作用[J]. 中国临床药理学与治理学, 2012, 17(7): 835-840.

[67] Bartels A L, Willemsen A T, Kortekaas R, et al. Decreased blood-brain barri-er P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA[J]. J Neural Transm, 2008, 115(7): 1001-1009.

[68] Terry P Brown, Paul C Rumsby, Alexander C Capleton, et al. Pesticides and Parkinson’s di-sease is there a link[J]. Environ Health Perspect, 2006, 114(2): 156-164.

[69] Sreeramulu K, Liu Rong-hua, Frances J Sharom. Interaction of insecticides with mammalian P-glycopertein and their effects on its transport function[J]. Biochim Biophys Acta, 2007, 1768(7): 1750-1757.

[70] Marie Westerlund, Andrea Carmine Belin, Lars Olson, et al. Expression of muti-drug resistan-ce1 mRNA in human and rodent tissue: reduced levels in Parkinson patients[J]. Cell Tissue Res, 2008, 334(2): 179-185.

[71] 牛芳，周芳，吴晓兰，王广基. 血脑屏障上ABC转运体与中枢神经系统疾病相关性的研究进展[J]. 中国临床药理学和治疗学, 2012, 17(2): 225-233.

[72] Zhang Chun-bo, Patrick Kwan, Zuo Zhong, et al. The transport of antiepileptic drugsby P-glycoprotein[J]. Adv Drug Delivery Rev, 2012, 64(10): 930-942.

[73] Bjorn Bauer, Anika M Hartz, Antom Pekcec, et al. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling [J]. Mol Pharmacol, 2008, 73(5): 1444-1453.

[74] Maria Feldmann, Matthias Koepp. P-glycoprotein imaging in temporal lobeepilepsy: in vivo PET experiments with the Pgp substrate[(11)C]-verapamil[J]. Epilepsia, 2012, 53(6): 60-63.

[75] 高敏，张敬军. P糖蛋白与难治性癫痫关系的研究进展[J]. 中国脑科疾病与康复杂志：电子版, 2016, 6(2): 120-123.

[76] Hiram Luna-Munguia, Heidrun Potschka. CNS transporters and drug delivery inepilepsy[J]. Curr Pharm Des, 2014, 20(10): 1534-1542.

[77] Andrew Owen, Becky Chandler, David J Back. The implications of P-glycoprotein in HI-V: friend or foe[J]? Fundam Clin Pharmacol, 2005, 19(3): 283-296.

[78] Kentaro Hayashi, Pu Hong, Ibolya E Andras, et al. HIV-Tat protein upregulates expression of multidrug resistance protein 1 in blood-brain barrier[J]. J Cereb Blood Flow Metab, 2006, 26(8): 1052-1065.

[79] Zhong Yu, Bernhard Hennig, Michal Toborek. Intact lipid rafts regulate HIV-1 Tat protein-induced activation of the Rho signaling and upregula-tion of P-glycoprotein in brain endothelial cells[J]. J Cereb BloodFlow Metab, 2010, 30(3):522-33.

[80] 雷燕,张建华,张明,等. P-糖蛋白抑制剂研究进展[J].广州化工, 2016, 44(6): 27-30.

[81] Hilary Thomas, Helen M Coley. Overcoming multidrug resistance in cancer: anupdate on the clinical strategy of inhibiting p-glycoprotein[J]. Cancercontrol, 2003, 10(2): 159-159.

[82] Nicola Antonio Colabufo, Francesco Berardi, Mariangela Cantore, et al. Perspectives of P-glycoprotein modulating agents in oncology and neuro-degenerative diseases: pharmace-utical, biological, and diagnostic potentials[J]. J Med Chem, 2010, 53(5): 1883-1897.

[83] 刘念，耿小平，熊茂明. P－糖蛋白抑制剂的研究进展[J]. 国外医学: 药学分册, 2006, 33(2): 107-110.

[84] Andreia Palmeira, Emilia Sousa, Vasconcelos M H, et al. Threedecades of P-gp inhi-bitors: skimming through severalgenerations and scaffolds[J]. Curr Med Che-m, 2012, 19(13): 1946-2025.

[85] 朱宝英,黄静,王永林,等. P-糖蛋白及肿瘤多药耐药的逆转[J]. 中国药房, 2011, 22(6): 550-552.

[86] Christopher A McDevitt, Richard Callaghan. How can we best usestructural information on P-glycoprotein to designinhibitors[J]? Pharm Ther, 2007, 113(2): 429-441.

[87] Lajos Pusztai, Peter Wagner, Nuhad Ibrahim, et al. Phase II study oftariquidar, a selective P-glycoprotein inhibitor, in patientswith chemotherapy-resistant, advanced breast carcinoma[J]. Cancer, 2005, 104(4): 682-691.

[88] Christine Y Malati, Sarah M Robertson, Jennifer D Hunt, et al. Influence of panaxginsengon cytochrome P450(CYP) 3A and P-glycoprotein(P-gp) activity in healthy subjects[J]. J Clin Pharmacol, 2012, 52(6): 932-939.

[89] Li Xue, Hu Jin-ping, Wang Bao-lian, et al. Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herbdrug interactions mediated via P-gp[J]. Toxicol Appl Pharm, 2014, 275(2): 163-175.

[90] Sun Yan-fang, Wink Michael. Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells[J]. Phytomedicine, 2014, 21(8-9): 1110-1119.

[91] Ye Ling, Wang Tao, Tang Lan, et al. Poor oral bioavailability of apromising anticancer agent andrographolide is due to extensivemetabolism and efflux by P-glycoprotein[J]. J Pharm Sci, 2011, 100(11): 5007-5017.

[92] Jiunn H Lin, Masayo Yamazaki. Role of P-glycoprotein in pharmacokinetics clinical implications[J]. Clin Pharmacokinet, 2003, 42(1): 59-98.